Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

While children under five, particularly those under two, are the most vulnerable, pneumococcal diseases also affect adults.

SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity ...

The ACIP-approved immunization schedules for children and adolescents and for adults for 2025 have been published.

Background: Pneumonia is the leading cause of morbidity and mortality among children ... magnitude of disease impact did not differ among schedules. Evidence for impact on pneumococcal pneumonia ...

Pfizer Prevnar ...

At first, much the same. But inevitably, dangerous diseases would resurge in a country that isn’t prepared for them.

According to the Centers for Disease Control and Prevention, children younger than five years of age and adults over 65 years of age are at increased risk for pneumococcal disease. Additionally, ...

One area of recent research is the development and implementation of pneumococcal ... diseases[1]. Another significant focus has been on the treatment of community-acquired pneumonia (CAP) in ...

All children collected samples with a bilateral nasal swab ... of the Brazilian Ministry of Health registered 360 events of bacterial meningitis and invasive pneumococcal diseases in 2020 (same year ...